MidFirst Bank’s Praxis Precision Medicines PRAX Stock Holding History

MidFirst Bank’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5	Closed	-$1.47K	–	993
2025 Q4	$1.47K	Buy	+5	New	+$931	﹤0.01%	691

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

MidFirst Bank's PRAX Position: Q1 2026 in Review

MidFirst Bank sold out of Praxis Precision Medicines (PRAX) in Q1 2026, closing a stake of 5 shares — an estimated $1.47K sold.

MidFirst Bank first reported a position in PRAX in Q4 2025 and held it in 1 quarter. The position peaked at $1.47K in Q4 2025. 290 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

MidFirst Bank reported no remaining Praxis Precision Medicines position as of Q1 2026 after selling out during the quarter.
MidFirst Bank sold 5 Praxis Precision Medicines shares in Q1 2026, an estimated $1.47K.
MidFirst Bank first reported a position in Praxis Precision Medicines in Q4 2025 and held it in 1 quarter.
MidFirst Bank's Praxis Precision Medicines position peaked at $1.47K in Q4 2025.
290 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on MidFirst Bank's 13F filing for Q1 2026, filed 15 May 2026.